SIGA Technologies Inc.
SIGASIGA Technologies Inc. is a biopharmaceutical company specializing in the development and commercialization of antiviral medications. The company is known for its products targeting biothreat agents and infectious diseases, with a focus on treatments for smallpox and other orthopoxvirus infections. SIGA's flagship drug, TPOXX (tecovirimat), is an antiviral approved for the treatment of smallpox and has been developed to address potential bioweapons threats.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| May 15, 2025 | $0.60 | 2025-04-29 | 2025-04-29 |
| April 11, 2024 | $0.60 | 2024-03-25 | 2024-03-26 |
| June 1, 2023 | $0.45 | 2023-05-15 | 2023-05-16 |
| June 2, 2022 | $0.45 | 2022-05-16 | 2022-05-17 |
Dividends Summary
- Consistent Payer: SIGA Technologies Inc. has rewarded shareholders with 4 dividend payments over the past 3 years.
- Total Returned Value: Investors who held SIGA shares during this period received a total of $2.10 per share in dividend income.
- Latest Payout: The most recent dividend of $0.60/share was paid 253 days ago, on May 15, 2025.
- Dividend Growth: Since 2022, the dividend payout has grown by 33.3%, from $0.45 to $0.60.
Company News
Healthcare stocks have been stagnant since April, but offer attractive dividend yields ranging from 5.3% to 7.1%. The article highlights several healthcare REITs and pharmaceutical companies with high dividend potential despite market challenges.
SIGA Technologies reported strong Q2 2025 financial performance, with revenue jumping 271.6% to $81.1 million, driven by major TPOXX antiviral therapy deliveries to U.S. government agencies. The company paid a special $0.60 per share dividend and maintained robust cash reserves.
The sustainable construction materials market is predicted to reach $734.9 billion by 2032, driven by the growing adoption of green certifications and standards. Companies are focusing on team training and understanding green benchmarks to strengthen their position in the evolving market. However, the adoption of sustainable materials faces chall...
SIGA Technologies, a biopharmaceutical company, is facing scrutiny over its disclosures regarding the potential expansion of its lead product, TPOXX®, to treat Mpox. The company's clinical trial for TPOXX® failed to meet its primary endpoint, leading to a significant drop in the stock price. SIGA also terminated its Chief Medical Officer, raisi...
SIGA Technologies' lead product TPOXX failed to meet its primary endpoint in a clinical trial for Mpox treatment, leading to a significant drop in the company's stock price. The company also terminated its Chief Medical Officer, raising further concerns about transparency.
